Novartis’ blockbuster Entresto received the US FDA approval for a broader target population Novartis has received the US FDA approval of Entresto ((sacubitril/valsartan) for the broader target population; it is now approved for p...
Merck and Bayer announced the US FDA approval for Verquvo Merck and Bayer have announced that the companies have received the US FDA's approval for Verquvo (vericiguat). The drug is approved for ...
Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients Biogen has announced that the first patient with spinal muscular atrophy (SMA) has been treated with Spinraza (nusinersen), who were prio...
Lynparza was approved for three more indications in Japan AstraZeneca and Merck announced that Lynparza (olaparib) was approved for three more indications in Japan. The three new cancer indicatio...
Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma Kite announced that it received conditional approval in Europe for Tecartus (brexucabtagene autoleucel). Tecartus is a chimeric antigen r...
Gilead received the approval of Jyseleca from the European and Japan regulatory authorities for RA Gilead has announced that it has received the approval for Jyseleca (filgotinib) from the regulatory authorities in the European Union an...
